Close Menu
Home › Inova Decides to End PGx Test Offerings in Response to FDA Warning Letter

Inova Decides to End PGx Test Offerings in Response to FDA Warning Letter

Apr 15, 2019
|
staff reporter

This article has been updated with a statement from the Clinical Pharmacogenetics Implementation Consortium.

NEW YORK (GenomeWeb) – Inova Health System has decided to completely stop performing its suite of pharmacogenetic tests in response to a US Food and Drug Administration warning letter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Regulatory News & FDA Approvals

  1. FDA Clears NantHealth Tumor-Normal Whole-Exome Test

  2. Becton Dickinson Submits HPV Assay for Expanded US Premarket Approval

  3. Agilent's Magnis Joins Set-and-Forget Movement in Library Prep Instruments

    Premium

  4. Siemens Healthineers, Thermo Fisher Scientific, DiaSorin and Others Get 510(k) Clearances in October

  5. Biocept Receives CE Mark for Blood Collection Tube, Sample Collection Shipping Kit

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.